CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM120117
035-os BibID:(WoS)001060565600002 (Scopus)85181657414
Első szerző:Ahmed, Sakir
Cím:Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis : survival analysis from a multicentre international patient?reported survey / Sakir Ahmed, Latika Gupta, Masataka Kuwana, John D. Pauling, Jessica Day, Naveen Ravichandran, Mrudula Joshi, Ioannis Parodis, Parikshit Sen, Kshitij Jagtap, Elena Nikiphorou, Sreoshy Saha, Vishwesh Agarwal, Tulika Chatterjee, James B. Lilleker, Sinan Kardes, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia?Ramos, Ai Lyn Tan, Arvind Nune, Lorenzo Cavagna, Miguel A. Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Oliver Distler, Suryo Anggoro Kusumo Wibowo, COVAD Study Group
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:This study aimed to assess the incidence, predictors, and outcomes of breakthrough infection (BI) following coronavirus disease (COVID-19) vaccination in patients with systemic sclerosis (SSc), a risk group associated with an immune-suppressed state and high cardiopulmonary disease burden. Cross-sectional data from fully vaccinated respondents with SSc, non-SSc autoimmune rheumatic diseases (AIRDs), and healthy controls (HCs) were extracted from the COVAD database, an international self-reported online survey. BI was defined according to the Centre for Disease Control definition. Infection-free survival was compared between the groups using Kaplan-Meier curves with log-rank tests. Cox proportional regression was used to assess the association between BI and age, sex, ethnicity, and immunosuppressive drugs at the time of vaccination. The severity of BI in terms of hospitalization and requirement for oxygen supplementation was compared between groups. Of 10,900 respondents, 6836 fulfilled the following inclusion criteria: 427 SSc, 2934 other AIRDs, and 3475 HCs. BI were reported in 6.3% of SSc, 6.9% of non-SSc AIRD, and 16.1% of HCs during a median follow-up of 100 (IQR: 60-137) days. SSc had a lower risk for BI than HC [hazard ratio (HR): 0.56 (95% CI 0.46-0.74)]. BIs were associated with age [HR: 0.98 (0.97-0.98)] but not ethnicity or immunosuppressive drugs at the time of vaccination. Patients with SSc were more likely to have asymptomatic COVID-19, but symptomatic patients reported more breathlessness. Hospitalization [SSc: 4 (14.8%), HCs: 37 (6.6%), non-SSc AIRDs: 32(15.8%)] and the need for oxygenation [SSc: 1 (25%); HC: 17 (45.9%); non-SSc AIRD: 13 (40.6%)] were similar between the groups. The incidence of BI in SSc was lower than that in HCs but comparable to that in non-SSc AIRDs. The severity of BI did not differ between the groups. Advancing age, but not ethnicity or immunosuppressive medication use, was associated with BIs.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Breakthrough infections
COVAD
COVID-19
Surveys and questionnaires
Systemic sclerosis
Megjelenés:Rheumatology International. - 44 : 1 (2023), p. 89-97. -
További szerzők:Gupta, Latika Kuwana, Masataka Pauling, John D. Day, Jessica Ravichandran, Naveen Joshi, Mrudula Parodis, Ioannis Sen, Parikshit Jagtap, Kshitij Nikiphorou, Elena (reumatológus) Saha, Sreoshy Agarwal, Vishwesh Chatterjee, Tulika Lilleker, James B. Kardes, Sinan Milchert, Marcin Gheita, Tamer A. Salim, Babur Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Tan, Ai Lyn Nune, Arvind Cavagna, Lorenzo Saavedra, Miguel A. Shinjo, Samuel Katsuyuki Ziade, Nelly Knitza, Johannes Distler, Oliver Wibowo, Suryo Anggoro Kusumo Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM117879
035-os BibID:(scopus)85162972096 (wos)001014747300001
Első szerző:Doskaliuk, Bohdana
Cím:Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies : results from the COVAD study / Doskaliuk Bohdana, Ravichandran Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Gracia-Ramos Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, La Torre Ignacio García-De, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akarawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi Lina El, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse event
Autoimmunity
COVID-19
Myositis
Surveys and questionnaires
Vaccination
Megjelenés:Rheumatology International. - 43 : 9 (2023), p. 1651-1664. -
További szerzők:Ravichandran, Naveen Sen, Parikshit Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Tehozol, Erick Adrian Zamora Serrano, Jorge Rojas La Torre, Ignacio García-De Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Hoff, Leonardo Santos Kibbi, Lina El Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM105749
035-os BibID:(scopus)85139571711 (wos)000840395200001
Első szerző:Fazal, Zoha Zahid
Cím:COVAD survey 2 long-term outcomes : unmet need and protocol / Fazal Zoha Zahid, Sen Parikshit, Joshi Mrudula, Ravichandran Naveen, Lilleker James B., Agarwal Vishwesh, Kardes Sinan, Kim Minchul, Day Jessica, Makol Ashima, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Parodis Ioannis, Nikiphorou Elena, Tan Ai Lyn, Chatterjee Tulika, Cavagna Lorenzo, Saavedra Miguel A., Shinjo Samuel Katsuyuki, Ziade Nelly, Selva-O'Callaghan Albert, Nune Arvind, Knitza Johannes, Kuwana Masataka, Gutiérrez Carlos-Enrique Toro, Caballero-Uribe Carlo Vinicio, Dey Dzifa, Distler Oliver, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2022
ISSN:0172-8172 1437-160X
Megjegyzések:Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoimmune diseases
COVID-19
Long-term adverse effects
Registries
Vaccination
Megjelenés:Rheumatology International. - 42 : 12 (2022), p. 2151-2158. -
További szerzők:Sen, Parikshit Joshi, Mrudula Ravichandran, Naveen Lilleker, James B. Agarwal, Vishwesh Kardes, Sinan Kim, Minchul Day, Jessica Makol, Ashima Milchert, Marcin Gheita, Tamer A. Salim, Babur Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Parodis, Ioannis Nikiphorou, Elena (reumatológus) Tan, Ai Lyn Chatterjee, Tulika Cavagna, Lorenzo Saavedra, Miguel A. Shinjo, Samuel Katsuyuki Ziade, Nelly Selva-O'Callaghan, Albert Nune, Arvind Knitza, Johannes Kuwana, Masataka Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Dey, Dzifa Distler, Oliver Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM120115
035-os BibID:(Scopus)85163056433 (WoS)001007661900004
Első szerző:Grignaschi, Silvia
Cím:High fatigue scores in patients with idiopathic inflammatory myopathies : a multigroup comparative study from the COVAD e-survey / Silvia Grignaschi, Minchul Kim, Giovanni Zanframundo, COVAD study group
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:Idiopathic inflammatory myopathies (IIMs) confer a significant risk of disability and poor quality of life, though fatigue, an important contributing factor, remains under-reported in these individuals. We aimed to compare and analyze differences in visual analog scale (VAS) scores (0-10 cm) for fatigue (VAS-F) in patients with IIMs, non-IIM systemic autoimmune diseases (SAIDs), and healthy controls (HCs). We performed a cross-sectional analysis of the data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) international patient self-reported e-survey. The COVAD survey was circulated from December 2020 to August 2021, and details including demographics, COVID-19 history, vaccination details, SAID details, global health, and functional status were collected from adult patients having received at least one COVID-19 vaccine dose. Fatigue experienced 1 week prior to survey completion was assessed using a single-item 10 cm VAS. Determinants of fatigue were analyzed in regression models. Six thousand nine hundred and eighty-eight respondents (mean age 43.8 years, 72% female; 55% White) were included in the analysis. The overall VAS-F score was 3 (IQR 1-6). Patients with IIMs had similar fatigue scores (5, IQR 3-7) to non-IIM SAIDs [5 (IQR 2-7)], but higher compared to HCs (2, IQR 1-5; P < 0.001), regardless of disease activity. In adjusted analysis, higher VAS-F scores were seen in females (reference female; coefficient -0.17; 95%CI -0.21 to -13; P < 0.001) and Caucasians (reference Caucasians; coefficient -0.22; 95%CI -0.30 to -0.14; P < 0.001 for Asians and coefficient -0.08; 95%CI -0.13 to 0.30; P = 0.003 for Hispanics) in our cohort. Our study found that patients with IIMs exhibit considerable fatigue, similar to other SAIDs and higher than healthy individuals. Women and Caucasians experience greater fatigue scores, allowing identification of stratified groups for optimized multidisciplinary care and improve outcomes such as quality of life.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoimmune diseases
COVID-19
Fatigue
Myositis
Surveys and questionnaires
Megjelenés:Rheumatology International. - 43 : 9 (2023), p. 1637-1649. -
További szerzők:Kim, Minchul Zanframundo, Giovanni Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM120114
035-os BibID:(Scopus)85159682435 (WoS)000961261800002
Első szerző:Naveen, R.
Cím:Systemic sclerosis and COVID-19 vaccine safety : short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey / Naveen R., Thakare Darpan R., Kuwana Masataka, Pauling John D., Day Jessica, Joshi Mrudula, Parodis Ioannis, Sen Parikshit, Jagtap Kshitij, Nikiphorou Elena, Saha Sreoshy, Agarwal Vishwesh, Chatterjee Tulika, Lilleker James B., Kardes Sinan, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Tan Ai Lyn, Nune Arvind, Cavagna Lorenzo, Saavedra Miguel A., Shinjo Samuel Katsuyuki, Ziade Nelly, Knitza Johannes, Distler Oliver, Chinoy, COVAD Study Group, Aggarwal Rohit, Gupta Latika, Agarwal Vikas, Makol Ashima
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively, and did not differ significantly with disease activity or different vaccine types, though with minor symptom differences. Frequencies of AEs were not affected by background immunosuppression, though SSc patients receiving hydroxychloroquine experienced fatigue less commonly (OR 0.4; 95% CI 0.2-0.8). Frequency of AEs and hospitalisations were similar to other AIRDs, nrAIDs, and HC except a higher risk of chills (OR 1.3; 95% CI 1.0-1.7) and fatigue (OR 1.3; 95% CI 1.0-1.6) compared to other AIRDs. COVID-19 vaccines were largely safe and well tolerated in SSc patients in the short term. Background immunosuppression and disease activity did not influence the vaccination-related short-term AEs.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse events
Autoimmune diseases
COVID-19
Systemic sclerosis
Vaccination
Megjelenés:Rheumatology International. - 43 : 7 (2023), p. 1265-1275. -
További szerzők:Thakare, Darpan R. Kuwana, Masataka Pauling, John D. Day, Jessica Joshi, Mrudula Parodis, Ioannis Sen, Parikshit Jagtap, Kshitij Nikiphorou, Elena (reumatológus) Saha, Sreoshy Agarwal, Vishwesh Chatterjee, Tulika Lilleker, James B. Kardes, Sinan Milchert, Marcin Gheita, Tamer A. Salim, Babur Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Tan, Ai Lyn Nune, Arvind Cavagna, Lorenzo Saavedra, Miguel A. Shinjo, Samuel Katsuyuki Ziade, Nelly Knitza, Johannes Distler, Oliver Aggarwal, Rohit Gupta, Latika Agarwal, Vikas Makol, Ashima Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM117880
035-os BibID:(WOS)001116143800001 (Scopus)85181481512
Első szerző:Panchawagh, Suhrud
Cím:COVID-19 breakthrough infections in type 1 diabetes mellitus : a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group / Panchawagh Suhrud, Ravichandran Naveen, Barman Bhupen, Nune Arvind, Javaid Mahnoor, Gracia-Ramos Abraham Edgar, Day Jessica, Joshi Mrudula, Kuwana Masataka, Saha Sreoshy, Pande Arunkumar R., Caballero-Uribe Carlo Vinicio, Velikova Tsvetelina, Parodis Ioannis, Knitza Johannes, Kadam Esha, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Boro Hiya, COVAD Study Group, Aggarwal Rohit, Agarwal Vikas, Chatterjee Tulika, Gupta Latika
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Breakthrough infections
COVID-19
Survey
Type 1 diabetes mellitus
Vaccine
Megjelenés:Rheumatology International. - 44 : 1 (2023), p. 73-80. -
További szerzők:Ravichandran, Naveen Barman, Bhupen Nune, Arvind Javaid, Mahnoor Gracia-Ramos, Abraham Edgar Day, Jessica Joshi, Mrudula Kuwana, Masataka Saha, Sreoshy Pande, Arunkumar R. Caballero-Uribe, Carlo Vinicio Velikova, Tsvetelina Parodis, Ioannis Knitza, Johannes Kadam, Esha Tan, Ai Lyn Shinjo, Samuel Katsuyuki Boro, Hiya Aggarwal, Rohit Agarwal, Vikas Chatterjee, Tulika Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.